Trending in Longevity

Semaglutide and tirzepatide now studied as multi-system gerotherapeutics with anti-inflammatory and cardiovascular longevity effects beyond weight loss.

DNA methylation-based biological age tools like DunedinPACE and GrimAge are now standard in longevity trials as primary outcome measures.

mTOR inhibitor generating major human trial data on immune resilience and cardiac function; PEARL trial results driving renewed excitement.

Yamanaka factor-based cellular rejuvenation is the most talked-about experimental longevity frontier, with multiple biotech companies now in trials.

Drugs that selectively clear senescent cells remain a core anti-aging drug class with multiple human translation trials now underway.

Multi-omics biological age panels are moving toward routine clinical care, with consumer products expanding access rapidly in 2025-2026.

NMN and nicotinamide riboside remain top longevity supplements, with new focus on delivery optimization and NAD+ depletion mechanisms.

Compounds that suppress the SASP without killing senescent cells are gaining traction as a complementary strategy alongside senolytics.

Empagliflozin and dapagliflozin gaining longevity interest after evidence of telomere preservation and senescence reduction beyond diabetes management.

Mitophagy activator from pomegranate metabolism now in human trials showing muscle and mitochondrial benefits in older adults.

HBOT protocols trending for reported telomere lengthening, senescent cell reduction, and cognitive benefits in aging adults.

Extracellular vesicles from young or stem-cell sources are heavily discussed in regenerative aging, though clinical evidence remains contested.

TAME trial results are the most anticipated geroscience clinical data point; metformin remains the flagship gerotherapeutic drug candidate.

Compounds blocking CD38, the primary NAD+-consuming enzyme, are central to the 'stop the NAD+ leak' strategy in longevity biology.

Valter Longo's ProLon protocol and FMD research showing measurable biological age reduction and immune system regeneration in clinical trials.

Cytokine panels and immune-aging readouts like IL-6, TNF-alpha, and CRP are core tools in quantifying chronic age-related inflammation.

The most studied senolytic drug combination, still the reference protocol in human senolytic trials and a benchmark for the field.

CGMs are now widely used for metabolic optimization and biological aging protocols, far beyond their original diabetes application.

Plasma protein-based biological age measures like the SomaScan atlas are emerging as powerful complements to DNA methylation clocks.

Klotho is gaining momentum as a longevity biomarker and potential therapeutic target with new data linking levels to brain aging and cognitive decline.

ApoB is now considered the primary cardiovascular longevity biomarker by leading longevity physicians, driving interest in aggressive LDL-lowering strategies.

Thymic rejuvenation strategies including TRIIM trial follow-ups and new thymosin-based protocols are gaining traction for immune aging reversal.

This gut bacterium is trending as a longevity microbiome target with human data showing metabolic and gut barrier benefits in aging populations.

Polyamine autophagy inducer gaining interest from food-sourced and supplemental forms with emerging human data on cardiovascular and cognitive aging.

Autologous stem cell preservation services are rapidly expanding as a longevity investment, driven by biotech marketing and aging biology awareness.

Bioactive peptides for tissue repair, recovery, and regeneration are exploding in longevity and biohacking communities despite limited clinical data.

Photobiomodulation devices are trending widely for mitochondrial activation, cognitive benefits, and skin aging with growing consumer and research interest.

Strawberry-derived flavonoid repeatedly cited in senolytic research and popular longevity circles for its selective clearance of senescent cells.

AKG is trending as a TCA cycle intermediate with epigenetic and longevity effects, popularized by Bryan Johnson and backed by emerging trial data.

TRT is increasingly framed in a longevity context following TRAVERSE trial cardiovascular safety data, driving broader healthspan conversations.

Often called 'nature's metformin,' berberine is widely discussed as an accessible AMPK activator and metabolic longevity supplement.

Mitochondrial electron carrier gaining renewed longevity attention for neuroprotection and cognitive function, trending in biohacking communities.

Dedicated healthspan clinics offering biological age testing, personalized protocols, and gerotherapeutics are proliferating rapidly worldwide in 2025-2026.

Glycine and NAC combination shown to restore glutathione levels and reverse multiple aging hallmarks in older adults in human clinical trials.

Despite controversy, telomere-lengthening strategies including TA-65 and TERT activation remain frequently discussed in longevity and aging circles.

Blood-based Alzheimer's biomarker now validated as a sensitive early detection tool, transforming dementia prevention discussions in longevity medicine.

Potent marine-derived antioxidant carotenoid discussed for anti-inflammatory and mitochondrial protection benefits in aging, trending among supplement users.

Emerging therapy transferring functional mitochondria from healthy cells to damaged tissues is gaining attention in rejuvenation and aging research.

Phospholipid supplement with renewed interest for brain aging, cognitive function, and neuronal membrane integrity in older adults.

Mapping gene expression across tissue architecture in aging organs is revealing cell-state changes that bulk RNA sequencing misses entirely.

Copper-binding tripeptide widely discussed for skin regeneration, wound healing, and broader systemic anti-aging effects in biohacking circles.

Glycomic profiling of IgG glycans as a biological age readout is gaining visibility as a novel inflammation and aging biomarker distinct from methylation clocks.